Most supplements are introduced with a long list of possible benefits. Luteolin is more interesting for a different reason: it has a specific metabolic target.

That target is fructokinase, also called ketohexokinase or KHK—the enzyme that begins fructose metabolism. In a 2017 study, researchers measured luteolin inhibiting KHK in a biochemical assay and in a human kidney-cell system. In mice, intravenous luteolin also reduced injury in a model where KHK itself was shown to be part of the damage.^[1]

This does not yet tell us how strongly an oral luteolin supplement inhibits KHK in people. But it gives us something unusually valuable: a defined enzyme, a measurable mechanism, and a human experiment that can be designed today.

The short answer: luteolin is an experimentally demonstrated fructokinase inhibitor. The important next question is whether an oral formulation can produce meaningful KHK inhibition in humans.

What is fructokinase—and why does it matter?

Fructokinase is the enzyme that phosphorylates fructose into fructose-1-phosphate. The high-activity KHK-C form is especially prominent in the liver, kidney and small intestine.

The reaction happens quickly and consumes ATP, the cell's immediately usable energy currency. Unlike a key early step in glucose metabolism, it is not restrained by the same feedback control. With a sufficiently large fructose load, intracellular phosphate and ATP can fall. AMP may then be degraded through the purine pathway, contributing to uric-acid production.^[2]

The sequence is simple enough to remember:

Fructose → KHK → fructose-1-phosphate → ATP consumption → AMP breakdown → uric acid

That energy shift helps explain why fructose is not metabolically identical to glucose, even though both contain calories. Glucose is principally a fuel. Fructose can also act as a fuel regulator, helping move metabolism toward energy storage and conservation.

Richard Johnson and colleagues have described this broader response as a “survival switch”: a program that may once have helped animals prepare for scarcity by conserving energy, stimulating food seeking and building fat stores.^[2] In that model, fructose is not a metabolic mistake. It is an elegant survival signal operating in an environment where concentrated sugar is now available all year.

The problem may be less about fructose existing than about how often the pathway is activated.

The body can make fructose too

Fructose does not only come from food. The body can make it from glucose through the polyol pathway:

Glucose → sorbitol → fructose

Human evidence confirms that this happens. In a small Yale experiment, researchers raised blood glucose in eight healthy adults while using magnetic resonance spectroscopy to track metabolites in the brain. Brain fructose rose as brain glucose rose, without a corresponding increase in circulating fructose.^[3]

Experimental research also shows that the polyol pathway can be activated by conditions such as high glucose, high osmolarity, dehydration and low oxygen.^{[1], [2]}

This changes how we think about the pathway. Reducing concentrated dietary sugar remains sensible, but it addresses only fructose entering from the diet. KHK sits one step further downstream, where fructose—whether eaten or produced inside the body—enters its distinctive metabolic cascade.

That makes KHK an unusually strategic target.

The experiment that put luteolin on the map

The most direct luteolin-KHK evidence comes from a 2017 Nature Communications study of ischemic acute kidney injury.^[1]

The researchers found that reduced blood flow and oxygen activated the polyol pathway in the kidney cortex. Sorbitol and endogenous fructose increased. Normal mice developed severe kidney injury accompanied by ATP depletion, higher uric acid, oxidative stress and inflammation. Mice genetically lacking KHK were substantially protected.

Then the team tested luteolin.

In a fructokinase activity assay, luteolin inhibited the enzyme with a reported IC50 of 11.2 micromolar. It also inhibited fructokinase activity in lysates from human proximal-tubule cells that express KHK.

The researchers next gave luteolin intravenously to mice at 2.5 mg/kg before and after the ischemic injury. Luteolin-treated animals had markedly lower creatinine and blood urea nitrogen, along with less tissue injury and lower urinary NGAL. When luteolin was given only after the injury, it produced a dose-dependent rise in urinary fructose—exactly the direction expected when fructose metabolism is being blocked—and a dose-dependent improvement in kidney injury.^[1]

That is unusually specific evidence for a natural compound. The researchers did not simply observe a lower inflammatory marker and work backward. They measured the enzyme, its inhibition and a metabolic consequence consistent with target engagement.

Luteolin has other biological effects, so the mouse outcome cannot be assigned to KHK inhibition alone. But the evidence converges: removing KHK genetically was protective, luteolin inhibited KHK directly, and treatment changed fructose handling in the expected direction.

Human KHK studies validate the target

Luteolin has not yet been tested as a KHK inhibitor in a human target-engagement trial. KHK itself, however, has.

In a randomized phase 1 study, a pharmaceutical KHK inhibitor called PF-06835919 was given to healthy adults. As the dose increased, plasma fructose rose—a pharmacodynamic sign that less fructose was being metabolized through KHK.^[4]

Researchers then tested the same compound in adults with fatty liver disease. In a six-week randomized phase 2a trial, the 300 mg dose significantly reduced whole-liver fat relative to placebo and improved inflammatory markers; the 75 mg dose did not significantly change the primary liver-fat endpoint.^[5]

A later 16-week trial enrolled adults with fatty liver disease and type 2 diabetes. The higher dose again reduced liver fat relative to placebo, although changes in HbA1c did not reach statistical significance.^[6]

These trials do not tell us that luteolin will reproduce a pharmaceutical inhibitor's effects. They establish the more important foundation: KHK can be inhibited in humans, target engagement can be measured, and changing the pathway can alter meaningful metabolic outcomes.

The target is real. The open question is whether oral luteolin can reach it strongly enough.

Oral luteolin is a delivery problem

A compound can inhibit an enzyme beautifully in a dish and still disappoint when swallowed.

Luteolin is extensively metabolized after ingestion. In a human absorption study, luteolin-3′-O-sulfate was the major form detected in plasma after oral luteolin.^[7] Other research also describes substantial glucuronidation and sulfation, with relatively limited exposure to unchanged luteolin.

But “poor bioavailability” is not the end of the question. The relevant issue is whether a particular dose and formulation can deliver luteolin—or an active metabolite—to the right tissue at a concentration that changes the target.

That is why liposomes, phospholipid complexes and other delivery systems are being explored. Better dispersion or absorption could matter. It still has to be demonstrated for each finished formulation.

Why athletes are an especially interesting test case

Athletes deliberately push energy metabolism. Training demands rapid ATP turnover; endurance events require careful management of carbohydrate, glycogen and hydration; recovery depends on restoring energy without unnecessarily prolonging inflammatory stress.

That does not make luteolin a proven performance enhancer. It makes trained, metabolically healthy people a revealing population in which to study the mechanism.

A University of Jordan trial is now evaluating 100 mg of oral luteolin daily for 12 weeks in 50 apparently healthy male athletes aged 18 to 35. Planned outcomes include VO2 max, Wingate performance, body composition, and expression of MEF2 and SREBP-1.^[8] As of September 2026, the registry lists the study as enrolling by invitation and reports no results.

The study is not designed to measure KHK inhibition, but its existence matters. Luteolin is moving from broad preclinical promise into controlled research on human metabolism and performance.

For athletes, the most useful question is not “Does luteolin burn fat?” It is more precise: does it alter fructose handling or cellular energy regulation in a way that can be measured during high metabolic demand?

The human experiment we should run next

The decisive first study does not need to be a multi-year weight-loss trial.

Researchers could recruit healthy adults, standardize their diet before testing, randomize them to luteolin or placebo, and administer a controlled fructose challenge. Multiple formulations or doses could be compared.

The study would track:

• plasma and urinary fructose;
• uric acid;
• glucose and insulin;
• lactate and related metabolites;
• luteolin and its major metabolites.

The core question would be narrow: Does oral luteolin change human fructose metabolism in a pattern consistent with KHK inhibition?

If the answer is yes, larger trials could then ask what the mechanism means for cravings, energy stability, fatty liver, healthy aging or athletic recovery. Mechanism first; outcomes second.

Where SugarShield fits

This research is one reason luteolin became central to LIV3 Health's formulation work.

SugarShield combines luteolin with a liposomal delivery system, reflecting both our interest in KHK as a metabolic control point and the practical absorption challenge of conventional luteolin.

The finished product has not been used in the KHK studies described above, and its formulation does not by itself prove human KHK inhibition. It is better understood as a practical application of the hypothesis: formulate around a plausible upstream target, improve delivery where possible, and test the model against both research and real-world experience.

For readers who want the wider pathway, the Fructose Metabolism Master Guide explains how ATP, uric acid, mitochondrial function and endogenous fructose may fit together. Our luteolin evidence guide examines the ingredient and its absorption in more detail.

A sharp hypothesis, not a finished story

Follow fructose metabolism upstream and you arrive at KHK. Follow KHK into the experimental literature and you find luteolin.

The evidence supports a confident, precise conclusion: luteolin directly inhibits fructokinase in biochemical and human kidney-cell systems, and intravenous luteolin was protective in a mouse model where KHK was independently shown to drive injury.^[1]

Now the question has become testable in people.

If oral luteolin produces a measurable KHK target-engagement signal, it would give researchers a new way to investigate fructose not simply as sugar, but as a regulator of cellular energy and fuel conservation. That possibility—not another vague list of “antioxidant benefits”—is what makes luteolin worth watching.

References

1. Andres-Hernando A, Li N, Cicerchi C, et al. Protective role of fructokinase blockade in the pathogenesis of acute kidney injury in mice. Nature Communications. 2017;8:14181. doi:10.1038/ncomms14181
2. Johnson RJ, Lanaspa MA, Sanchez-Lozada LG, et al. The fructose survival hypothesis for obesity. Philosophical Transactions of the Royal Society B. 2023;378:20220230. doi:10.1098/rstb.2022.0230
3. Hwang JJ, Jiang L, Hamza M, et al. The human brain produces fructose from glucose. JCI Insight. 2017;2:e90508. doi:10.1172/jci.insight.90508
4. Gutierrez JA, Liu W, Perez S, et al. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. Molecular Metabolism. 2021;48:101196. doi:10.1016/j.molmet.2021.101196
5. Kazierad DJ, Chidsey K, Somayaji VR, et al. Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: a randomized phase 2 trial. Med. 2021;2:800–813.e3. doi:10.1016/j.medj.2021.04.007
6. Saxena AR, Lyle SA, Khavandi K, et al. A phase 2a study of PF-06835919 in patients with non-alcoholic fatty liver disease and type 2 diabetes. Diabetes, Obesity and Metabolism. 2023;25:992–1001. doi:10.1111/dom.14946
7. Hayasaka N, Shimizu N, Komoda T, et al. Absorption and metabolism of luteolin in rats and humans in relation to in vitro anti-inflammatory effects. Journal of Agricultural and Food Chemistry. 2018;66:11320–11329. doi:10.1021/acs.jafc.8b03273
8. University of Jordan. Evaluating the role of luteolin supplementation in cellular metabolism, physical performance, and body composition in athletes. ClinicalTrials.gov identifier NCT07280520. ClinicalTrials.gov record